2.1.3.1	Carcinoma	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28270654&form=6&db=m	A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.	causal interaction,therapeutic application,unassigned	3,1,0	
2.1.3.1	Carcinoma, Ehrlich Tumor	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6508821&form=6&db=m	Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.	diagnostic usage,ongoing research,unassigned	3,1,0	
2.1.3.1	methylmalonyl-coa carboxytransferase deficiency	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33279518&form=6&db=m	Development of Gene Therapy Vectors: Remaining Challenges.	causal interaction,therapeutic application,unassigned	1,4,0	
2.1.3.1	Neoplasms	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6508821&form=6&db=m	Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.	diagnostic usage,ongoing research,unassigned	3,1,0	
2.1.3.1	Urea Cycle Disorders, Inborn	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28270654&form=6&db=m	A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.	causal interaction,therapeutic application,unassigned	3,1,0